Zealand Pharma A/S (OCSE:ZEAL) EV-to-EBITDA : -49.73 (As of May. 18, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma A/S EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zealand Pharma A/S's enterprise value is kr35,759.8 Mil. Zealand Pharma A/S's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr-719.1 Mil. Therefore, Zealand Pharma A/S's EV-to-EBITDA for today is -49.73.

The historical rank and industry rank for Zealand Pharma A/S's EV-to-EBITDA or its related term are showing as below:

OCSE:ZEAL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -60.59 Med: -12.26 Max: 8.02
Current: -49.73

During the past 13 years, the highest EV-to-EBITDA of Zealand Pharma A/S was 8.02. The lowest was -60.59. And the median was -12.26.

OCSE:ZEAL's EV-to-EBITDA is ranked worse than
100% of 455 companies
in the Biotechnology industry
Industry Median: 10.35 vs OCSE:ZEAL: -49.73

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-18), Zealand Pharma A/S's stock price is kr600.00. Zealand Pharma A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-12.580. Therefore, Zealand Pharma A/S's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Zealand Pharma A/S EV-to-EBITDA Historical Data

The historical data trend for Zealand Pharma A/S's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S EV-to-EBITDA Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

Get a 7-Day Free Trial

-12.93

-12.19

-7.91

-12.08

-30.77

Zealand Pharma A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBITDA	Get a 7-Day Free Trial															-10.40	-13.45	-22.64	-30.77	-56.79

Competitive Comparison of Zealand Pharma A/S's EV-to-EBITDA

For the Biotechnology subindustry, Zealand Pharma A/S's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma A/S's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's EV-to-EBITDA falls into.

Zealand Pharma A/S EV-to-EBITDA Calculation

Zealand Pharma A/S's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	35759.820	/	-719.065
	=	-49.73

Zealand Pharma A/S's current Enterprise Value is kr35,759.8 Mil.
Zealand Pharma A/S's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-719.1 Mil.

Zealand Pharma A/S (OCSE:ZEAL) EV-to-EBITDA Explanation

Zealand Pharma A/S's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	600.00	/	-12.580
	=	At Loss

Zealand Pharma A/S's share price for today is kr600.00.
Zealand Pharma A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-12.580.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Zealand Pharma A/S EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (OCSE:ZEAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OCSE:ZEAL) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

ZLDPF:USA ZEALc:UK 0NZU:UK 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.